Compugen Ltd.

Headquarters: Holon, Israel

Investor Relations: Yvonne Naughton, PhD / +1 (628) 241-0071 / ir@cgen.com

Description

Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors.

Industry

Life Sciences

Year Founded

Website

Ownership

Public

Exchange / Symbol

NYSE: CGEN

Public Since

Chief Executive Officer

Chairman of the Board

Chief Financial Officer

Insider Ownership

Key Investors

Employee Count

Trailing Revenues

Trailing Operating Profits

Trailing Net Income

Auditors

Investment Bankers

Law Firm

In the CEOs Own Words

Corporate Mission

Proudest Accomplishment

Next Milestone

Geographic Markets Served

Growth Drivers

Growth Headwinds

Indicia of Customer Satisfaction

Scalability

Workforce

Focus of Recruitment

Research and Development

Patent Count

Economic Sensitivity

Unique Metrics

Greatest Concern

Company Reports and Communications

Company Press Releases

SEC Filings

Reports

Podcasts

Open Questions to Management

Chatboard

Yahoo Finance

Yahoo Finance